A kit comprising the composition of claim 10 packaged with a means for endoscopic injection.Ģ2. A kit comprising the composition of claim 1 packaged with a means for endoscopic injection.Ģ1. A method as set forth in claim 18 wherein the internal site is in the gastrointestinal tract, urinary bladder or lungs.Ģ0. A method for staining of an internal site comprising injecting the composition of claim 14 in a staining amount in proximity to the site.ġ9. A method as set forth in claim 16 wherein the internal site is in the gastrointestinal tract, urinary bladder or lungs.ġ8. A method for staining of an internal site comprising injecting the composition of claim 1 in a staining amount in proximity to the site.ġ7. An endoscopic staining composition as set fourth in claim 11, said composition comprising: about 0.01% to about 1.0% carbon pigment, about 5% to about 25% glycerol, about 0.005% to about 0.05% simethicone, about 0.5% to about 1.5% polyoxyethylene sorbitan esterified with fatty acid, zero to about 2.0% benzyl alcohol, and sufficient water for a 100% composition.ġ6. A composition as set forth in claim 13 wherein the suspending/viscosity-increasing agent comprises glycerol, propylene glycol, isopropylene glycol, polyethylene glycol or cellulose, the anti-foaming agent comprises dimethicone or simethicone, and the surfactant comprises polyoxyethylene sorbitan esterified with fatty acid.ġ5. A composition as set forth in claim 10 comprising: about 0.1% to about 10% carbon pigment, about 10% to about 20% suspending/viscosity-increasing agent, about 0.0 1% to about 0.04% anti-foaming agent, about 0.5% to about 1.5% surfactant, and water to yield 100% composition based on weight.ġ4. A composition as set forth in claim 11 wherein the suspending/viscosity-increasing agent comprises glycerol, propylene glycol, isopropylene glycol, polyethylene glycol or cellulose, the anti-foaming agent comprises dimethicone or simethicone, and the surfactant comprises polyoxyethylene sorbitan esterified with fatty acid.ġ3.
A composition as set forth in claim 10, said composition comprising: about 0.01% to about 1.0% carbon pigment, about 5.0% to about 25% suspending/viscosity-increasing agent, about 0.005% to about 0.05% anti-foaming agent, about 0.5% to about 1.5% surfactant, and water as a delivery vehicle to yield 100% composition based on weight.ġ2.
An endoscopic tissue staining composition comprising a carbon pigment, a suspending/viscosity-increasing agent, a surfactant, and an anti-foaming agent in a pharmaceutically acceptable delivery vehicle, wherein said carbon pigment has a level of total polycyclic aromatic hydrocarbons of not greater than 0.5 ppm.ġ1. A composition as set forth in claim 1 wherein the carbon pigment comprises particles of carbon black, activated carbon or unactivated carbon.ġ0.
A composition as set forth in claim 1 wherein the delivery vehicle comprises water.ĩ. A composition as set forth in claim 6 wherein said anti-foaming agent comprises dimethicone or simethicone.Ĩ. A composition as set forth in claim 1 wherein said composition further comprises an anti-foaming agent.ħ. A composition as set forth in claim 4 wherein said surfactant comprises polyoxyethylene sorbitan esterified with fatty acid.Ħ. A composition as set forth in claim 1 wherein said composition further comprises a surfactant.ĥ. A composition as set forth in claim 1 wherein the suspending/viscosity-increasing agent comprises glycerol, propylene glycol, isopropylene glycol, polyethylene glycol or cellulose.Ĥ. A composition as set forth in claim 1 wherein said composition is non-cytotoxic.ģ. An endoscopic tissue staining composition comprising a carbon pigment and a suspending/viscosity-increasing agent in a pharmaceutically acceptable delivery vehicle, wherein said carbon pigment has a level of total polycyclic aromatic hydrocarbons of not greater than 0.5 ppm.Ģ.
0 kommentar(er)
